Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Introduction: To evaluate the fundus autofluorescence (FAF) images 1 year after half-dose photodynamic therapy (hdPDT) for chronic central serous chorioretinopathy (CSC). Methods: Forty-six eyes of 46 consecutive patients with chronic CSC underwent hdPDT. Short wavelength-elicited FAF images and enh...

Full description

Bibliographic Details
Main Authors: Kyoko Fujita, Yutaka Imamura, Kei Shinoda, Soiti Matsumoto, Mitsuko Yuzawa
Format: Article
Language:English
Published: Karger Publishers 2020-12-01
Series:Biomedicine Hub
Subjects:
Online Access:https://www.karger.com/Article/FullText/512662
id doaj-a1f71942ca204eaa9421c454466e089d
record_format Article
spelling doaj-a1f71942ca204eaa9421c454466e089d2021-01-28T15:17:52ZengKarger PublishersBiomedicine Hub2296-68702020-12-01611510.1159/000512662512662Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous ChorioretinopathyKyoko FujitaYutaka ImamuraKei ShinodaSoiti MatsumotoMitsuko YuzawaIntroduction: To evaluate the fundus autofluorescence (FAF) images 1 year after half-dose photodynamic therapy (hdPDT) for chronic central serous chorioretinopathy (CSC). Methods: Forty-six eyes of 46 consecutive patients with chronic CSC underwent hdPDT. Short wavelength-elicited FAF images and enhanced depth imaging optical coherence tomographic (EDI-OCT) images were recorded before and at 1, 3, 6, 9, and 12 months after the hdPDT. The FAF images at 1 month were compared to those at 12 months after the hdPDT. Results: The serous retinal detachment (SRD) was resolved in all eyes. The best-corrected visual acuity (BCVA) improved significantly from 0.13 ± 0.28 logarithm of minimum angle of resolution (logMAR) units before to 0.01 ± 0.17 logMAR units at 12 months after the hdPDT (p = 0.001; paired t test). The mean choroidal thickness decreased significantly from 365.4 ± 103.0 µm to 284.3 ± 92.5 µm at 12 months (p < 0.001). Abnormal FAF images were present within the irradiated area in all the eyes before the hdPDT. In 5 of 46 eyes, identifiable changes of the FAF images were observed 12 months after hdPDT. None of the eyes had the confluent hypo-FAF type during the follow-up period. Univariate analyses showed that the choroidal thickness before hdPDT correlated significantly with hypo-FAF enlargement (p = 0.005). However, multivariate analyses showed that the association was not significant (p = 0.06). Conclusions: The progression of the RPE damages occurred in approximately one-tenth of the eyes that underwent hdPDT for chronic CSC. The long-term effect of progression of hypo-FAF on visual functions remains to be determined.https://www.karger.com/Article/FullText/512662central serous chorioretinopathyfundus autofluorescencephotodynamic therapy
collection DOAJ
language English
format Article
sources DOAJ
author Kyoko Fujita
Yutaka Imamura
Kei Shinoda
Soiti Matsumoto
Mitsuko Yuzawa
spellingShingle Kyoko Fujita
Yutaka Imamura
Kei Shinoda
Soiti Matsumoto
Mitsuko Yuzawa
Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Biomedicine Hub
central serous chorioretinopathy
fundus autofluorescence
photodynamic therapy
author_facet Kyoko Fujita
Yutaka Imamura
Kei Shinoda
Soiti Matsumoto
Mitsuko Yuzawa
author_sort Kyoko Fujita
title Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
title_short Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
title_full Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
title_fullStr Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
title_full_unstemmed Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
title_sort fundus autofluorescence after half-dose photodynamic therapy for chronic central serous chorioretinopathy
publisher Karger Publishers
series Biomedicine Hub
issn 2296-6870
publishDate 2020-12-01
description Introduction: To evaluate the fundus autofluorescence (FAF) images 1 year after half-dose photodynamic therapy (hdPDT) for chronic central serous chorioretinopathy (CSC). Methods: Forty-six eyes of 46 consecutive patients with chronic CSC underwent hdPDT. Short wavelength-elicited FAF images and enhanced depth imaging optical coherence tomographic (EDI-OCT) images were recorded before and at 1, 3, 6, 9, and 12 months after the hdPDT. The FAF images at 1 month were compared to those at 12 months after the hdPDT. Results: The serous retinal detachment (SRD) was resolved in all eyes. The best-corrected visual acuity (BCVA) improved significantly from 0.13 ± 0.28 logarithm of minimum angle of resolution (logMAR) units before to 0.01 ± 0.17 logMAR units at 12 months after the hdPDT (p = 0.001; paired t test). The mean choroidal thickness decreased significantly from 365.4 ± 103.0 µm to 284.3 ± 92.5 µm at 12 months (p < 0.001). Abnormal FAF images were present within the irradiated area in all the eyes before the hdPDT. In 5 of 46 eyes, identifiable changes of the FAF images were observed 12 months after hdPDT. None of the eyes had the confluent hypo-FAF type during the follow-up period. Univariate analyses showed that the choroidal thickness before hdPDT correlated significantly with hypo-FAF enlargement (p = 0.005). However, multivariate analyses showed that the association was not significant (p = 0.06). Conclusions: The progression of the RPE damages occurred in approximately one-tenth of the eyes that underwent hdPDT for chronic CSC. The long-term effect of progression of hypo-FAF on visual functions remains to be determined.
topic central serous chorioretinopathy
fundus autofluorescence
photodynamic therapy
url https://www.karger.com/Article/FullText/512662
work_keys_str_mv AT kyokofujita fundusautofluorescenceafterhalfdosephotodynamictherapyforchroniccentralserouschorioretinopathy
AT yutakaimamura fundusautofluorescenceafterhalfdosephotodynamictherapyforchroniccentralserouschorioretinopathy
AT keishinoda fundusautofluorescenceafterhalfdosephotodynamictherapyforchroniccentralserouschorioretinopathy
AT soitimatsumoto fundusautofluorescenceafterhalfdosephotodynamictherapyforchroniccentralserouschorioretinopathy
AT mitsukoyuzawa fundusautofluorescenceafterhalfdosephotodynamictherapyforchroniccentralserouschorioretinopathy
_version_ 1724319660807028736